Cramer: Apple Is Th...
Health Care: Drugs
Aastrom Biosciences Inc. (ASTM: NASDAQ)
$1.96 -0.03 | -1.51%
06/01/12 - 03:59 PM ET
Company Income Statement
| Dec 2011 | Dec 2010 | Jun 2010 | Jun 2009 | |
| Sales | 18.00K | 253.00K | 89.00K | 182.00K |
| Cost of Sales | -643.00K | -257.00K | -558.00K | -562.00K |
| Gross Operating Profit | 661.00K | 510.00K | 647.00K | 744.00K |
| Selling, General, and Administrative Expenses | 7.72M | 3.26M | 5.20M | 4.95M |
| Research & Development | 21.33M | 8.61M | 12.66M | 11.29M |
| Operating Income before D & A (EBITDA) | -28.39M | -11.36M | -17.21M | -15.50M |
| Depreciation & Amortization | 647.00K | 259.00K | 592.00K | 674.00K |
| Interest Income | 53.00K | 40.00K | 115.00K | 296.00K |
| Other Income - Net | 9.33M | -7.50M | 0.00 | 0.00 |
| Special Income / Charges | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Income Before Interest Expenses (EBIT) | -19.66M | -19.08M | -17.69M | -15.87M |
| Interest Expense | 10.00K | 5.00K | 40.00K | 73.00K |
| Pre-Tax Income | -19.67M | -19.09M | -17.73M | -15.95M |
| Income Taxes | 0.00 | 0.00 | 0.00 | 0.00 |
| Minority Interest | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Income From Continuing Operations | -19.67M | -19.09M | -17.73M | -15.95M |
| Net Income From Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Income From Total Operations | -19.67M | -19.09M | -17.73M | -15.95M |
| Extraordinary Income/Losses | 0.00 | 0.00 | 0.00 | 0.00 |
| Income From Cum. Effect of Acct. Change | 0.00 | 0.00 | 0.00 | 0.00 |
| Income From Tax Loss Carryforward | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Gains / Losses | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Net Income | -19.67M | -19.09M | -17.73M | -15.95M |
| Normalized Income (Net Income From Continuing Operations, Ex. Special Income / Charge) |
-19.67M | -19.09M | -17.73M | -15.95M |
| Preferred Dividends | ||||
|---|---|---|---|---|
| Net Income Available To Common | -19.67M | -19.09M | -17.73M | -15.95M |
| Basic EPS from Continuing Ops. | -0.51 | -0.65 | -0.72 | -0.88 |
| Basic EPS from Discontinued Ops. | 0.00 | 0.00 | 0.00 | 0.00 |
| Basic EPS from Total Operations | -0.51 | -0.65 | -0.72 | -0.88 |
| Basic EPS from Extraordinary Inc. | 0.00 | 0.00 | 0.00 | 0.00 |
| Basic EPS from Cum Effect of Accounting Change | 0.00 | 0.00 | 0.00 | 0.00 |
| Basic EPS from Tax Loss Carryf'd. | 0.00 | 0.00 | 0.00 | 0.00 |
| Basic EPS from Other Gains (Losses) | 0.00 | 0.00 | 0.00 | 0.00 |
| Basic EPS, Total | -0.51 | -0.65 | -0.72 | -0.88 |
| Basic Normalized Net Income/Share | -0.51 | -0.65 | -0.72 | -0.88 |
| EPS fr Continuing Ops. | -0.51 | -0.65 | -0.72 | -0.88 |
| EPS fr Discontinued Ops | 0.00 | 0.00 | 0.00 | 0.00 |
| EPS fr Total Ops. | -0.51 | -0.65 | -0.72 | -0.88 |
| EPS fr Extraord. Inc. | 0.00 | 0.00 | 0.00 | 0.00 |
| EPS fr Cum Effect of Accounting Change | 0.00 | 0.00 | 0.00 | 0.00 |
| EPS fr Tax Loss Carfd. | 0.00 | 0.00 | 0.00 | 0.00 |
| EPS fr Other Gains (L) | 0.00 | 0.00 | 0.00 | 0.00 |
| EPS, Total | -0.51 | -0.65 | -0.72 | -0.88 |
| Diluted Normalized Net Inc/Shr (Net Income From Continuing Operations, Ex. Special Income / Charge) |
-0.51 | -0.65 | -0.72 | -0.88 |
| Dividends Paid per Share | 0.00 | 0.00 | 0.00 | 0.00 |
Portfolios with ASTM
- Portfolio NameUser Type
- ContributorBreakout Stocks Of The Week...
- Contributor10 Cheap Biotech Stocks Tha...
- Usermrtimrx WatchList
- UserMy Folly
- Userbosw119
- Usergellis1360 Portfolio 1
- UserSusu's Stocks
- UserRet2009
- Userspecialinterest
- Userpo boy
Latest ASTM Headlines from TheStreet
- Aastrom Raises Cash To Fund Pivotal Trial 03.09.12 | 12:03 pm
- More Biotech Twitter Mailbag: Orexigen, Affymax, YM Bio, Spectrum & More 02.29.12 | 07:02 am
- Aastrom CEO: Financing Close to Completion 01.18.12 | 08:01 am
- Aastrom Cell Therapy Reverses Effects of Blocked Leg Arteries 11.14.11 | 02:11 pm
- The Next Big Thing In Biotech: Aastrom
11.11.11 | 05:11 am - Biotech Calendar: Key Dates for November 11.01.11 | 10:11 am
- Biotech Calendar: Key Dates for September 08.31.11 | 06:08 am
- 10 Cheap Biotech Stocks That Could Soar 06.28.11 | 07:06 am
- Biotech Stock Mailbag: Live Chat 06.17.11 | 11:06 am
- Biotech Stock Mailbag: Aastrom BioSciences 06.03.11 | 06:06 am
Press Releases for ASTM
Partner Headlines for ASTM
- Follow the Analyst Leader: New Stock Coverage to Watch - Wall St. Cheat Sheet 05.31.12 | 04:05 am
- Medgenics Moving In Record Time - Seeking Alpha 05.21.12 | 09:05 am
- Aastrom Biosciences Announces Initiation of Patient Enrollment in REVIVE Phase 3 Clinical Trial of Ixmyelocel-T - Benzinga 02.29.12 | 04:02 pm
- 10 Biotech Stocks Undervalued By Levered Free Cash Flows - Seeking Alpha 12.07.11 | 08:12 am
- Aastrom Bio: Final RESTORE Data Looks Solid - Seeking Alpha 11.15.11 | 09:11 am
- 6 Recently Crushed Stocks With Heavy New Insider Buying - Seeking Alpha 08.14.11 | 09:08 am
- Analyst Interview - International Stem Cell - Analyst Blog - Zacks 07.27.11 | 06:07 am
- Aastrom Files At-the-Market Offering and New Shelf Registration Statement - Benzinga 06.16.11 | 04:06 pm
- Aastrom Biosciences' Trial Meets Safety and Efficacy Endpoints - Seeking Alpha 06.02.11 | 09:06 am
- 6 Speculative Biotech Stocks Smart Money Loves - Seeking Alpha 05.23.11 | 09:05 am
